Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Small-Cell Lung Cancer (US)
The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (AstraZeneca; 2020) compete for market share in the first-line treatment setting for extensive-stage disease. In September 2024, Tecentriq Hybreza, a subcutaneous formulation of Tecentriq, also entered this space. In the later-line extensive-stage setting, prescribers can choose between the RNA polymerase II inhibitor Zepzelca (PharmaMar; 2020) and, recently, the DLL3-targeting T-cell engager Imdelltra (Amgen; 2024).
Questions answered
- What are the treatment rates for SCLC in the various stages and lines of therapy?
- How are new therapy entrants to the SCLC market performing relative to existing therapies?
- What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?
- What are the rates of testing for different biomarkers?
Product description
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
- Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.
Markets covered: United States
Primary research: Survey of 101 medical oncologists in the United States fielded in February 2025
Key drugs: Tecentriq, Tecentriq Hybreza, Imfinzi, Zepzelca, Imdelltra
